# Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

> **NCT01473810** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 24 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** Vacc-4x low dose
- **BIOLOGICAL:** Vacc-4x medium dose
- **BIOLOGICAL:** Vacc-4x high dose
- **BIOLOGICAL:** Zero dose

## Key facts

- **NCT ID:** NCT01473810
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-06-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473810, "Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01473810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*